First gene therapy — ‘a true living drug’ — on the cusp of FDA approval – Washington Post
pharmaphorum |
First gene therapy — ‘a true living drug’ — on the cusp of FDA approval
Washington Post The CAR T-cell treatment, manufactured by the drug company Novartis, initially would be available only for the small number of children and young adults whose leukemia doesn’t respond to standard care. Those patients typically have a grim prognosis … Novartis CAR–T safety in FDA spotlightpharmaphorum |
|
BioMarin’s Investigational Gene Therapy for Hemophilia A at 6e13 vg/kg Dose Maintains Average Factor VIII Levels …
Stockhouse BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today an update to its previously reported interim results of an open-label Phase 1/2 study of BMN 270, an investigational gene therapy treatment for severe hemophilia A. The updated results will be … |
|
BioMarin’s Investigational Gene Therapy for Hemophilia A at 6e13 vg/kg Dose Maintains Average Factor VIII Levels …
PR Newswire (press release) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported interim results of an open-label Phase 1/2 study of BMN 270, an investigational gene therapy treatment for severe hemophilia A. The updated results will … |
|
Regenerating the Body With Stem Cells – Hype or Hope?
Labiotech.eu (blog) When the Japanese researcher Shinya Yamanaka managed to reprogram adult cells into an embryonic-like state to yield induced pluripotent stem cells (iPSCs), this was supposed to herald a revolution in regenerative medicine. But 10 years after their … Stem Cell Banking Market To Grow at a CAGR of +18% by 2021 According to new researchMedgadget (blog) |
|
UPDATE 1-FDA panel to focus on safety of Novartis gene therapy …
Business Insider July 10 (Reuters) – The U.S. Food and Drug Administration will ask a panel of advisors to focus on the safety of Novartis AG’s experimental gene therapy drug … Novartis’ CAR-T Therapy for Pediatric Leukemia to Face FDA Advisory PanelAJMC.com Managed Markets Network |
BU Today |
CReM Stem Cell Researcher Is Innovator of the Year
BU Today Those who know ancient history—the first decade of the 21st century—recall that embryonic stem cell research was a combustible issue, with supporters cheering the potential to create new tissues from stem cells and opponents decrying the destruction … |